ReviewClinical and translational medicine2026
Spatiotemporal transcriptomics for tumour microenvironment remodelling in cancer progression and therapy.
Review in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSpatiotemporal transcriptomics (STT) integrates spatially resolved gene expression with temporal information derived from staged samples, paired treatment specimens, or computational inference, providing a framework for reconstructing tissue-level dynamics. In the tumour microenvironment (TME), STT extends static molecular and cellular maps by revealing how cellular neighbourhoods and functional niches are reorganised during tumour evolution. MAIN TEXT: This review examines how STT characterises TME remodelling during malignant transformation, invasion, metastasis, ageing, and treatment response. We discuss strategies for resolving temporal dynamics, including stage-stratified sampling, paired or serial specimens, pseudotime and trajectory inference, and complementary intravital imaging. We further consider how spatiotemporal analyses can connect changes in cellular states, spatial organisation, and intercellular interactions with clinically relevant tumour phenotypes.
conclusionBy linking the spatial organisation of the TME with stage- and treatment-associated molecular changes, STT may improve the prioritisation of candidate targets, treatment stratification, and the development of precision oncology strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.